Codexis Inc CDXS

Morningstar Rating
$1.48 +0.02 (1.02%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CDXS is trading at a LOCK|WRP^F premium.
Price
$1.47
Fair Value
LOCK|^>#^?pm
Uncertainty
LOCK|Pk
1-Star Price
LOCK|?!?#Yn
5-Star Price
LOCK|%?%<>$<
Economic Moat
LOCK|!%
Capital Allocation

Trading Information

Previous Close Price
$1.47
Day Range
$1.431.50
52-Week Range
$0.962.98
Bid/Ask
$1.40 / $1.54
Shares Outstanding
110.06M
Market Cap
$162.07M
Volume/Avg
477,570 / 1M

Key Statistics

Price/Earnings (Normalized)
Price/Sales
1.73
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
Total Yield
< 0.01%

Company Profile

Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
146

Valuation

Metric
CDXS
Price/Earnings (Normalized)
Price/Book Value
4.12
Price/Sales
1.73
Price/Cash Flow
Price/Earnings
CDXS

Financial Strength

Metric
CDXS
Quick Ratio
2.83
Current Ratio
3.06
Interest Coverage
−5.05
Quick Ratio
CDXS

Profitability

Metric
CDXS
Return on Assets (Normalized)
−16.63%
Return on Equity (Normalized)
−49.64%
Return on Invested Capital (Normalized)
−16.95%
Return on Assets
CDXS

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|?WW&Y<WLOCK|@Q#!>$131B
Regeneron Pharmaceuticals Inc
REGN
LOCK|VqGPZ>LOCK|$h&p$$80B
argenx SE ADR
ARGX
LOCK|WMM$?wRLOCK|j>%$62B
Moderna Inc
MRNA
LOCK|%<ltb?^LOCK|!GC$57B
BeOne Medicines Ltd ADR
ONC
LOCK|wk^LLjfLOCK|RL>$40B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|w@k>!<&LOCK|R?@^$33B
Royalty Pharma PLC Class A
RPRX
LOCK|hV?v<NV^LOCK|Vd^b<$26B
Incyte Corp
INCY
LOCK|j&@hRpLOCK|%^$25B
BioNTech SE ADR
BNTX
LOCK|J?W<MFLOCK|v>$24B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|!V&pBQ%LOCK|!C$16B

Sponsor Center